We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe
News

Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe

Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe
News

Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cytori received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE, to investigate adipose-derived stem and regenerative cells (ADRCs), processed by the Celution® One System, in the treatment of patients with acute heart attacks. This is the first country and trial-center approval for ADVANCE.

Additional country and trial-center approvals are anticipated throughout Europe during the first half of 2011. One of the goals of the trial is to expand the Celution® System CE Mark to include acute heart attack claims and to provide economic data to justify its implementation and reimbursement.

ADVANCE is a randomized, placebo controlled, double-blind trial that will enroll up to 360 patients with ST-elevation myocardial infarction in up to 35 centers, predominately in Europe. The primary endpoint of the trial is reduction in infarct size as measured by cardiac magnetic resonance imaging (MRI).

ADVANCE will use the Celution® One, our next generation device manufactured by Olympus-Cytori Joint Venture. The Celution® One System draws on the same core technology and scientific innovation as the Celution® 800 System, which is currently approved in Europe for breast reconstruction, certain aesthetic procedures and specific types of wounds.

The Celution® One System is an investigational device that is not yet commercially available. The Celution® One System is specifically designed for use in a hospital setting, processing greater tissue volumes in less time.

In 2010, Cytori reported results from the APOLLO trial, a pilot study for acute heart attack patients who underwent ADRC therapy. The study showed that the harvest and injection of ADRCs were safe and well-tolerated in this patient population. At 6 months, the procedure was associated with an improvement in infarct size in ADRC-treated patients, as well as in other measures.

Advertisement